Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
University of California Irvine
Search grants from University of California Irvine
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Kappa Receptor Antagonists as Rapid Acting Antidepressants
Veterinarian Training in Zoonotic Diseases in Developing Countries
Clinical Relevance of Circulating Prostatic Tumor Cells
Cardiac Protein Synthesis: Overload, Alcohol & Anoxia
Computer Studies of Flexibility in Proteins
Recently added grants:
Glucagon Regulation by A Novel Brown Adipose Factor
Genetic Control and Ileo-Colonic Mucosal Expression of Bile Acid-Related Mechanisms in Irritable Bowel Syndrome-Diarrhea
Molecular pathways underlying organ-specific targeting by the vagus nerve
High-Resolution, Anisotropic MR Elastography of the Brain
Molecularly targeted photothermal ablation to enhance the therapeutic efficacy of immunomodulatory therapies in hepatocellular carcinoma
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CA075019-006
Application #
6828778
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2003
Total Cost
Indirect Cost
Institution
Name
University of California Irvine
Department
Type
DUNS #
City
State
Country
Zip Code
Related projects
NIH 2003
N01 CA
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
/ University of California Irvine
NIH 2002
N01 CA
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
/ University of California Irvine
Publications
Beeram, M; Tan, Q-T N; Tekmal, R R et al.
(2007)
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
Ann Oncol 18:1323-8
Comments
Be the first to comment on this grant